Terns Pharmaceuticals

Data from our Phase 1 study evaluating our investigational oral #GLP-1R agonist in healthy adults with #obesity or overweight were featured in an Endpoints News article. The promising results reinforce the potential of our investigational therapy to address obesity, both as a standalone treatment and in combination with our #smallmolecule product candidates. We look forward to sharing more updates as we advance our obesity program and prepare for Phase 2 clinical trials in 2025. Read the full article here: https://lnkd.in/gbXGFaey

#ICYMI: We hosted a virtual key opinion leader event led by our Chief Executive Officer, Amy Burroughs, Chief Medical Officer, Emil Kuriakose, MD, and Andreas Hochhaus, M.D., Professor, Internal Medicine, Head of the Department of Hematology and Medical Oncology at the Jena University Hospital, and Director of the Comprehensive Cancer Center Central Germany, to highlight the potential of our chronic myeloid leukemia program and discuss how to interpret early #CML datasets.  Thank you for joining us, Dr. Hochhaus! Watch a replay of the event at https://lnkd.in/eZWiGzNG 

Today during #ESHCML2024, our team presented previously reported data on our proprietary allosteric BCR-ABL tyrosine kinase inhibitor (#TKI) for chronic myeloid leukemia (#CML) during two poster presentations.       These findings mark an important step forward in our CML program, showcasing the potential of our allosteric BCR-ABL TKI as a promising alternative to standard active site inhibitors. To learn more, stop by our Terns booth in the exhibit hall throughout the conference!     European School of Haematology (ESH) International CML Foundation

Attending ESH-#iCMLf 26th Annual John Goldman Conference on Chronic Myeloid Leukemia (#CML): Biology and Therapy (#ESHCML2024) this week? We’d love to meet you! Stop by the Meridian Room to explore our latest research Our team will present data from our CML development program during two poster presentations today at 6:50 pm CET. Meet us at the Terns Booth in the exhibit hall Stop by our booth during the conference! Chat with the team, learn more about the Phase 1 CARDINAL trial, and discuss how we're working to transform the landscape of CML treatment. European School of Haematology (ESH) International CML Foundation

#ICYMI: Last week, we shared positive top-line results from our Phase 1 clinical trial evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of our investigational oral GLP-1R agonist in healthy adults with #obesity or overweight. This milestone is a significant step forward in our clinical development program for metabolic disorders, and we’re excited to advance into Phase 2 in 2025. For more details, read the full release here: https://lnkd.in/e6VXMJ5U

#HiringAlert: Are you passionate about regulatory strategy and quality excellence? We are #hiring a Vice President, Regulatory Affairs & Quality Assurance.  This leadership role is a unique opportunity to shape the success of our development-stage programs by driving regulatory strategies, managing global health authority interactions, and overseeing quality operations. Join us in advancing innovative therapies and making a difference in patients' lives. Learn more: https://lnkd.in/eaC7CEUU #RegulatoryAffairs #QualityAssurance #ClinicalDevelopment #BiopharmaJobs #LeadershipOpportunity #JoinOurTeam #BiotechCareers

Today is #WCMLD24, a global initiative by CML Advocates Network to raise awareness for chronic myeloid leukemia (#CML), a rare but important #bloodcancer that represents 10% of all leukemia cases. While CML often requires lifelong management, advances in research and treatment have allowed many patients to lead fulfilling lives. On this day, we stand in solidarity with the global CML community, highlighting the critical need for ongoing research, patient support, and advocacy. As part of our ongoing commitment, our team made blankets and wrote personalized notes to provide comfort and encouragement to those affected by blood cancers. We stand together on #WorldCMLDay! 🌍❤️ Learn more: https://lnkd.in/eHypqKC

We’re presenting during #ESHCML2024! Join us in Prague next week, where we will present two posters highlighting data from our chronic myeloid leukemia (#CML) development program and Phase 1 CARDINAL trial.    European School of Haematology (ESH) International CML Foundation

Thanks, Reuters, for highlighting the positive progress from our early-stage study evaluating our approach to addressing the global challenge of #obesity. The article underscores the importance of developing competitive, once-daily treatments in the rapidly evolving weight-loss market. As we prepare to advance into mid-stage clinical trials next year, we remain focused on making a meaningful impact for patients and the broader healthcare community. https://lnkd.in/eiMSh_5q 

September is Leukemia & Lymphoma Month. With chronic myeloid #leukemia being a lifelong chronic condition requiring ongoing management, our efforts at Terns are focused on developing innovative therapies that can make a meaningful difference in people's lives. We understand the challenges faced by those living with CML, and we are dedicated to advancing research and treatment options that offer hope and improve quality of life. Access to multiple lines of treatment is crucial for improving outcomes in #CML. Our Phase 1 CARDINAL trial, a global study evaluating the safety and potential efficacy of our proprietary allosteric BCR-ABL inhibitor, seeks to offer new options for individuals who may benefit from alternative treatments. Learn more: https://lnkd.in/d2cXYKC #BloodCancerAwarenessMonth